BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 10, 2026
Home » Blogs » BioWorld MedTech Perspectives » FDA, devices and doom and gloom

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / Diagnostics / CDRH / FDA

FDA, devices and doom and gloom

May 25, 2011
By Mark McCarty

Is the sky falling? Device makers keep saying so

By MARK McCARTY

Medical Device Daily Washington Editor

FDA's Center for Devices and Radiological Health is certainly on a regulatory tear of late, and industry is understandably rattled by some of the developments. After all, CDRH only recently managed to shed a couple of obvious malcontents in the persons of Robert Smith, MD, and Julian Nichols, MD, who both worked at the Office of Device Evaluation at CDRH and were not exactly happy to get their walking papers. My impression is that you have to be either really obnoxious, noticeably incompetent, or both to lose a job with Uncle Sam, so it's difficult to avoid the conclusion that these two had some serious baggage and went out of their way to make trouble.

Even without the aforementioned renegades, industry has a lot of gripes about how things are done at CDRH, which is notoriously underfunded and unable to keep pace with everything that lands in its lap. Still, industry has a bad habit of declaring small device makers an endangered species. This didn't seem entirely speculative in early 2009, when the economy tottered on the verge of collapse. Back then, changes were on the horizon at FDA, venture capital looked nervous, and the U.S. Patent and Trademark Office was bogged down with roughly three quarters of a million patent applications with an average pendency of 36 months.

Things have stabilized since then, but the doomsday talk hasn't abated. For instance, I recently interviewed the principal of a small device firm who said industry was carefully watching the fate of his company's application and that a failure by FDA to approve the application would have “dire” consequences for the entire industry.

To some extent, a reworking of the approval and clearance processes at CDRH was needed, although some of the proposals put forth by the agency seem a bit off the charts. All the same, this business of saying in more or less veiled terms that the sky is falling is just absurd. When you look at per-capita income in the U.S. and the sheer amounts spent on healthcare here, the concept that device makers will utterly abandon the U.S. is just silly. And claiming industry will bail out is dishonest, because we all know better.

Just for the record, I don't go to church – not routinely anyway – and haven't since the age of 15, so I can't say for certain I'd know the Crack of Doom if I heard it. All the same, I'm not deaf, and I know that even in the face of Euro-flight, device makers will still want and need the U.S. market for at least as long as any of us are alive. After all, who can say no to a market measured in the trillions of dollars?

So please industry, no more apocalyptic forecasts. It's getting old. Not interesting, just old.

Is this really necessary?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Art concept for inflammation in the intestines

    Kymera’s IRF5 degrader shows potential in IBD treatment

    BioWorld Science
    At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing